{"created":"2021-03-01T06:36:28.705618+00:00","id":28394,"links":{},"metadata":{"_buckets":{"deposit":"8d88ca9a-3c2d-4625-b663-3f1377f7bc2c"},"_deposit":{"id":"28394","owners":[],"pid":{"revision_id":0,"type":"depid","value":"28394"},"status":"published"},"_oai":{"id":"oai:nagoya.repo.nii.ac.jp:00028394","sets":["499:500:501"]},"author_link":["92905"],"item_10_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2019-04","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"8","bibliographicPageEnd":"1752","bibliographicPageStart":"1751","bibliographicVolumeNumber":"79","bibliographic_titles":[{"bibliographic_title":"Cancer Research","bibliographic_titleLang":"en"}]}]},"item_10_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"The study by Filipczak and colleagues identified the interplay between mutant p53 proteins and methylcytosine dioxygenase ten-eleven translocation 1 (TET1) in lung cancers. p53 transversion mutations were closely associated with high TET1 expression, which prevented genomic instability–associated cellular senescence. Depletion of TET1 was synergistic with classical antitumor drugs, such as cisplatin or doxorubicin, providing an attractive rationale for targeted therapies against TET1 combined with antitumor drugs in patients with p53-mutant lung cancer.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_10_description_5":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"ファイル公開：2020/04/01","subitem_description_language":"ja","subitem_description_type":"Other"}]},"item_10_publisher_32":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"American Association for Cancer Research","subitem_publisher_language":"en"}]},"item_10_relation_11":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1158/0008-5472.CAN-19-0645","subitem_relation_type_select":"DOI"}}]},"item_10_select_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_select_item":"author"}]},"item_10_source_id_61":{"attribute_name":"ISSN（print）","attribute_value_mlt":[{"subitem_source_identifier":"0008-5472","subitem_source_identifier_type":"PISSN"}]},"item_1615787544753":{"attribute_name":"出版タイプ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Kondo, Yutaka","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"92905","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-04-01"}],"displaytype":"detail","filename":"Kondo_Commentary_for_Filizczak_CAN-18-1234.pdf","filesize":[{"value":"194.2 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"Kondo_Commentary_for_Filizczak_CAN-18-1234","objectType":"fulltext","url":"https://nagoya.repo.nii.ac.jp/record/28394/files/Kondo_Commentary_for_Filizczak_CAN-18-1234.pdf"},"version_id":"d6ec1395-368f-4064-af6f-9b8dd567f8c3"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Genome–Epigenome–Senescence: Is TET1 a Caretaker of p53-Injured Lung Cancer Cells ?","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Genome–Epigenome–Senescence: Is TET1 a Caretaker of p53-Injured Lung Cancer Cells ?","subitem_title_language":"en"}]},"item_type_id":"10","owner":"1","path":["501"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2019-08-09"},"publish_date":"2019-08-09","publish_status":"0","recid":"28394","relation_version_is_last":true,"title":["Genome–Epigenome–Senescence: Is TET1 a Caretaker of p53-Injured Lung Cancer Cells ?"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-01-16T04:21:08.938543+00:00"}